Israeli therapeutics company Kamada sets terms for $60 million U.S. IPO
Kamada, which is focused on orphan drugs and plasma-derived
protein therapeutics, announced terms for its IPO on Wednesday.
The Ness Ziona, Israel-based company plans to raise $60 million
by offering 5.6 million shares at a price of $10.75. At the
proposed price, Kamada would command a market value of $369
million. The company currently trades on the Tel Aviv Stock
Exchange under the ticker KMDA.
Kamada, which was founded in 1990 and booked $66 million in sales for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol KMDA. Kamada initially filed confidentially on January 24, 2013. Morgan Stanley and Jefferies & Co. are the joint bookrunners on the deal.